Randomized, Double-Blind, Placebo-Controlled Study of Sitaxsentan to Improve Impaired Exercise Tolerance in Patients With Heart Failure and a Preserved Ejection Fraction

A novel potent vasoconstrictor peptide produced by vascular endothelial cells

Masashi Yanagisawa, Hiroki Kurihara, Sadao Kimura et al. · Nature · 1988 · 10.8K citations · Full text

Life Sciences, Cell Biology, Physiology +9

ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC

John J.V. McMurray, Stamatis Adamopoulos, Stefan D. Anker et al. · European Heart Journal · 2012 · 6.9K citations · Full text

Medicine, Cardiology, Internal Medicine +12

Trends in Prevalence and Outcome of Heart Failure with Preserved Ejection Fraction

Theophilus Owan, David O. Hodge, Regina M. Herges et al. · New England Journal of Medicine · 2006 · 4.2K citations

Medicine, Cardiology, Internal Medicine +14

Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial

Salim Yusuf, Marc A. Pfeffer, Karl Swedberg et al. · The Lancet · 2003 · 3K citations

Medicine, Cardiology, Internal Medicine +12

Irbesartan in Patients with Heart Failure and Preserved Ejection Fraction

Barry M. Massie, Peter E. Carson, John J.V. McMurray et al. · New England Journal of Medicine · 2008 · 1.9K citations · Full text

Medicine, Cardiology, Internal Medicine +12